{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:06:49Z","timestamp":1793138809288,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded partly by the Prisoner of Conscience Appeal Fund and supported by Brad-ATTAIN, University of Bradford"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer is a significant global health issue, with resistance to doxorubicin (DOX) posing a major challenge to effective treatment. SUMOylation, a post-translational modification process, is linked to cancer progression and therapy resistance. PIAS4, a SUMO E3 ligase involved in maintaining genome stability and stress response, may play a role in these mechanisms. However, its function in breast cancer progression and DOX resistance remains uncertain. This study investigates the potential role of PIAS4 in mediating DOX resistance in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Naked mole-rats (NMRs) are cancer-resistant rodents with improved genome maintenance, yet the role of SUMOylation in this trait remains unclear. SUMOylation machinery gene expression levels are investigated using qPCR in NMR tissue in comparison with carcinogenic breast cancer (MCF-7) cell line. Functional studies are performed in MCF-7 cells overexpressing PIAS4 to demonstrate effects on proliferation, invasion, drug sensitivity, and protein expression in the presence and absence of DOX treatment. While most SUMOylation genes were expressed at low levels in NMR intestinal tissues, PIAS4 showed higher expression compared to MCF-7 cells. PIAS4 overexpression in MCF-7 cells significantly decreases colony formation, invasiveness, and resistance to DOX. Western blot analysis showed downregulated Bcl-2 protein levels after DOX treatment, indicating a potential role in apoptosis evasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PIAS4 expression level plays a role in breast cancer cell survival, invasiveness, and chemoresistance, partly by altering anti-apoptotic pathways. These findings position PIAS4 as a potential biomarker and therapeutic target for overcoming resistance to anthracycline-based therapies in breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-025-11423-0","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:35:58Z","timestamp":1769762158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity"],"prefix":"10.1007","volume":"53","author":[{"given":"Mohammed A. M.","family":"Salih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M. A. E. L.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A. S.","family":"Elrewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritchie","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-9447","authenticated-orcid":false,"given":"Sriharsha","family":"Kantamneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"3","key":"11423_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11423_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288\u2013300","journal-title":"JAMA"},{"issue":"2","key":"11423_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229","journal-title":"Pharmacol Rev"},{"key":"11423_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615\u2013627","journal-title":"Annu Rev Med"},{"issue":"3","key":"11423_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc.2016.143","volume":"17","author":"JS Seeler","year":"2017","unstructured":"Seeler JS, Dejean A (2017) SUMO and the robustness of cancer. Nat Rev Cancer 17(3):184\u2013197","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"11423_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13059-014-0422-2","volume":"15","author":"A Nayak","year":"2014","unstructured":"Nayak A, M\u00fcller S (2014) SUMO-specific proteases\/isopeptidases: senps and beyond. Genome Biol 15(7):422","journal-title":"Genome Biol"},{"issue":"11","key":"11423_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"K Shuai","year":"2003","unstructured":"Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3(11):900\u2013911","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"11423_CR8","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00018-009-0061-z","volume":"66","author":"MM Rytinki","year":"2009","unstructured":"Rytinki MM, Kaikkonen S, Pehkonen P, J\u00e4\u00e4skel\u00e4inen T, Palvimo JJ (2009) PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 66(18):3029\u20133041","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"11423_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/0008-5472.CAN-16-2958","volume":"77","author":"A Rabellino","year":"2017","unstructured":"Rabellino A, Andreani C, Scaglioni PP (2017) The role of PIAS SUMO E3-ligases in cancer. Cancer Res 77(7):1542\u20131547","journal-title":"Cancer Res"},{"issue":"1","key":"11423_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10409238.2020.1738332","volume":"55","author":"A Rabellino","year":"2020","unstructured":"Rabellino A, Khanna KK (2020) The implication of the sumoylation pathway in breast cancer pathogenesis and treatment. Crit Rev Biochem Mol Biol 55(1):54\u201370","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"7458","key":"11423_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12234","volume":"499","author":"X Tian","year":"2013","unstructured":"Tian X, Azpurua J, Hine C et al (2013) High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 499(7458):346\u2013349","journal-title":"Nature"},{"issue":"7814","key":"11423_CR12","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/s41586-020-2410-x","volume":"583","author":"F Hadi","year":"2020","unstructured":"Hadi F, Kulaberoglu Y, Lazarus KA et al (2020) Transformation of naked mole-rat cells. Nature 583(7814):E1\u2013E7","journal-title":"Nature"},{"issue":"2","key":"11423_CR13","doi-asserted-by":"publisher","first-page":"G188","DOI":"10.1152\/ajpgi.00080.2024","volume":"327","author":"J Aguilera-Lizarraga","year":"2024","unstructured":"Aguilera-Lizarraga J, Ritoux A, Bulmer DC, Smith ES (2024) Intestinal barrier function in the naked mole-rat: an emergent model for Gastrointestinal insights. Am J Physiol Gastrointest Liver Physiol 327(2):G188\u2013G201","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"35","key":"11423_CR14","doi-asserted-by":"publisher","first-page":"37706","DOI":"10.18632\/oncotarget.5342","volume":"6","author":"ML Tomasi","year":"2015","unstructured":"Tomasi ML, Ryoo M, Ramani K et al (2015) Methionine adenosyltransferase \u03b12 sumoylation positively regulates Bcl-2 expression in human colon and liver cancer cells. Oncotarget 6(35):37706\u201337719","journal-title":"Oncotarget"},{"issue":"5","key":"11423_CR15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.molcel.2009.06.033","volume":"35","author":"Y Galanty","year":"2009","unstructured":"Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP (2009) BRCA1 recruitment to damaged chromatin is regulated by the SUMO E3 ligase PIAS1. Mol Cell 35(5):563\u2013573","journal-title":"Mol Cell"},{"issue":"9","key":"11423_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ni1104","volume":"5","author":"B Liu","year":"2004","unstructured":"Liu B, Yang R, Wong KA et al (2004) PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 5(9):891\u2013898","journal-title":"Nat Immunol"},{"issue":"7275","key":"11423_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature08657","volume":"462","author":"Y Galanty","year":"2009","unstructured":"Galanty Y, Belotserkovskaya R, Coates J et al (2009) Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462(7275):935\u2013939","journal-title":"Nature"},{"issue":"12","key":"11423_CR18","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00018-003-3129-1","volume":"60","author":"D Schmidt","year":"2003","unstructured":"Schmidt D, M\u00fcller S (2003) PIAS\/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60(12):2561\u20132574","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"11423_CR19","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","volume":"111","author":"JC Reed","year":"2008","unstructured":"Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111(7):3322\u20133330","journal-title":"Blood"},{"issue":"5","key":"11423_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/sj.bjc.6605736","volume":"103","author":"SJ Dawson","year":"2010","unstructured":"Dawson SJ, Makretsov N, Blows FM et al (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 103(5):668\u2013675","journal-title":"Br J Cancer"},{"issue":"7","key":"11423_CR21","first-page":"628","volume":"17","author":"X He","year":"2017","unstructured":"He X, Riceberg J, Soucy T et al (2017) Targeting sumoylation pathway for cancer therapy: progress and perspectives. Curr Cancer Drug Targets 17(7):628\u2013638","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11423-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:35:59Z","timestamp":1769762159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11423-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11423"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11423-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. SK is CEO, founding director and shareholder of Hado Therapeutics Ltd (Registered in the UK: 12240559).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"336"}}